Angitia Biopharmaceuticals is a clinical‑stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases. The company is advancing three biologic product candidates in the clinic for osteoporosis, osteogenesis imperfecta, and spinal fusion, leveraging extensive scientific expertise in novel drug development. With a global outlook, Angitia aims to address key unmet medical needs in bone health and skeletal disorders.